The Roche subsidiary has just announced that the restructuring of its early development group, which was confirmed a month ago, was part of a 103-person cut in staff.
The South San Francisco-headquartered business already admitted back in June that its vice presidents Vishva Dixit, Man-Wah Tan, and Todd McDevitt were among the casualties of the latest round of layoffs. Genentech didn’t disclose at the time how many other jobs would be impacted.
Now, Genentech says it will be eliminating “103 positions across several areas,” including the changes at Genentech Research and Early Development (gRED) group, “as well as in other parts of the organization.”
It may be worth reiterating that the bulk of those are focused adjustments within Genentech that affect a small percentage of the company, and we are still on the Genentech hiring spree, including gRED,” a spokesperson wrote. Our hiring philosophy is based on the strengths, knowledge, and science disciplines that are most essential to the portfolio and the provision of innovative medicines to patients today and tomorrow.
The 103 job cuts are the latest in a series of restructuring cuts at Genentech, which last year fired at least 489 workers, including some who received pink slips as part of a global manufacturing restructuring by the Switzerland-based Roche group. In April last year (2024), Roche reduced the workforce by 3%, impacting 436 people on Genentech’s payroll.
Genentech confirmed the latest job cuts as it agreed to pay $25 million to Otsuka Pharmaceutical’s subsidiary Astex Pharmaceuticals as part of an agreement to find new drugs for breast cancer.
Astex has had several partnerships with Big Pharma, including with Merck & Co., AstraZeneca and Janssen, who were among the first to partner with Astex for its fragment-based drug discovery platform in the mid-2000s and since went on to develop the blockbuster breast cancer drug Kisqali.
In today’s deal, Cambridge, U.K.-based Astex will be entitled to up to $490 million in milestone payments from Genentech, which also will pay Astex tiered royalties based on net sales of medicines developed from the assets.
The newly announced collaboration is expected to focus on accelerating the development of innovative therapies for breast cancer by combining complementary scientific expertise and research capabilities. Strategic partnerships like this enable biotechnology companies to share resources, reduce development risks, and speed the transition of promising discoveries from laboratory research into clinical trials.
As cancer treatment becomes increasingly personalized, collaborations that integrate advanced biomarkers, molecular profiling, and targeted therapies are playing a larger role in improving patient outcomes.
Organizational Changes Reflect Industry Trends
Research organizations across the pharmaceutical industry continue to reassess how resources are allocated in response to changing scientific priorities and market conditions. Workforce adjustments are often part of broader efforts to simplify organizational structures, eliminate overlapping functions, and redirect investment toward high-priority research programs with the greatest potential for clinical impact.
Although restructuring can be challenging for affected employees, companies often view these changes as necessary to maintain long-term competitiveness and sustain innovation.
Genentech has announced a significant strategic move by entering a $490 million breast cancer partnership while simultaneously reducing its workforce by 103 employees as part of its gRED Rethink initiative. The latest developments highlight Genentech’s commitment to strengthening its oncology pipeline while restructuring research operations to improve efficiency and accelerate scientific innovation.
Genentech Expands Breast Cancer Research Through New Partnership
The partnership is expected to combine scientific expertise, clinical development capabilities, and advanced research platforms to accelerate the discovery of innovative therapies.
Expanding external collaborations can enhance every stage of the drug development process, from early discovery through late-stage clinical trials. Access to specialized technologies and scientific expertise may improve candidate selection, accelerate clinical development, and increase the likelihood of regulatory success.
These partnerships also create opportunities to evaluate combination therapies and explore new treatment strategies for patients with difficult-to-treat cancers.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
